Difference between revisions of "Gefitinib (Iressa)"
Jump to navigation
Jump to search
(FDA approval) |
m (→Also known as) |
||
| (32 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). | + | Class/mechanism: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Activating mutations of EGFR can drive tumor growth by activating pathways that promote proliferation, invasion, angiogenesis, metastasis, and inhibition of cell death. Gefitinib binds to the EGFR tyrosine kinase domain and inhibits these over-active signalling pathways. There are differences between specific EGFR mutations and their likelihood of clinical response to EGFR TKIs.<ref name="insert">[http://www.astrazeneca-us.com/cgi-bin/az_pi.cgi?product=iressa&country=us Gefitinib (Iressa) package insert]</ref><ref>[[:File:Gefitinib.pdf | Gefitinib (Iressa) package insert (locally hosted backup)]]</ref><ref>[https://www.iressa-usa.com Iressa manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| + | **[[Non-small cell lung cancer, nonsquamous]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.astrazeneca-us.com/cgi-bin/az_pi.cgi?product=iressa&country=us Gefitinib (Iressa) package insert]<ref name="insert"></ref> | *[http://www.astrazeneca-us.com/cgi-bin/az_pi.cgi?product=iressa&country=us Gefitinib (Iressa) package insert]<ref name="insert"></ref> | ||
| − | *[ | + | *[https://chemocare.com/druginfo/gefitinib.aspx Gefitinib (Iressa) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/gefitinib.aspx Gefitinib (Iressa) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/gefitinib-patient-drug-information Gefitinib (Iressa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/gefitinib-patient-drug-information Gefitinib (Iressa) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/gefitinib-patient-drug-information Gefitinib (Iressa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/gefitinib-patient-drug-information Gefitinib (Iressa) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | ===[[Non-small cell lung cancer]] - '''PARTIALLY WITHDRAWN'''=== |
| − | * | + | *2003-05-05: Granted accelerated approval as monotherapy for the treatment of patients with locally advanced or metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer]] after failure of both [[Regimen_classes#Platinum-based_regimen|platinum-based]] and [[Docetaxel (Taxotere)|docetaxel]] chemotherapies. ''(Based on IDEAL2)'' |
| − | * | + | **2005-06-17: Due to the negative confirmatory trial, access of this drug was restricted to patients currently receiving and benefiting from Iressa; patients who have previously received and benefited from Iressa; and previously enrolled patients or new patients in non-Investigational New Drug (IND) clinical trials approved by an IRB prior to June 17, 2005. ''(Based on ISEL)'' |
| + | **2012-04-25: Accelerated approval withdrawn. | ||
| + | *2015-07-13: [http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm454692.htm FDA approved] for the first-line treatment of patients with metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] whose tumors have [[Biomarkers#EGFR|epidermal growth factor receptor (EGFR)]] [[Biomarkers#Exon_19|exon 19]] [[Biomarkers#Deletion|deletions]] or [[Biomarkers#L858R|exon 21 (L858R) substitution]] mutations. ''(Based on IFUM and IPASS)'' | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *2009-06-24: Initial marketing authorization as Iressa. | ||
| + | ==History of changes in Health Canada indication== | ||
| + | *2003-12-17: Initial notice of compliance with conditions | ||
| + | *2009-12-18: Conditions were met | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2011-11-25: Revised indication for the treatment of unresectable advanced or recurrent [[non-small cell lung cancer]] in patients with EGFR gene mutation. | ||
| + | |||
| + | ==Resistance and sensitivity mechanisms== | ||
| + | # Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29. [https://doi.org/10.1056/NEJMoa040938 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15118073/ PubMed] | ||
| + | # Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24;352(8):786-92. [https://doi.org/10.1056/NEJMoa044238 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15728811/ PubMed] | ||
==Also known as== | ==Also known as== | ||
| − | + | *'''Code name:''' ZD-1839 | |
| + | *'''Brand names:''' Cangib, Denrit, Geffy, Gefitec, Gefitero, Gefonib, Geftib, Geftican, Gefticip, Geftilon, Geftinat, Geftiwel, Iressa, KabiGef, Tykessa | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Oral medications]] |
| − | [[Category: | + | [[Category:Mutation-specific medications]] |
| + | |||
| − | |||
[[Category:EGFR inhibitors]] | [[Category:EGFR inhibitors]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
| − | [[Category: | + | [[Category:EMA approved in 2009]] |
| − | [[Category: | + | [[Category:FDA approved in 2003]] |
| + | [[Category:Health Canada approved in 2003]] | ||
| + | [[Category:FDA approved in 2015]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 14:34, 11 June 2024
General information
Class/mechanism: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Activating mutations of EGFR can drive tumor growth by activating pathways that promote proliferation, invasion, angiogenesis, metastasis, and inhibition of cell death. Gefitinib binds to the EGFR tyrosine kinase domain and inhibits these over-active signalling pathways. There are differences between specific EGFR mutations and their likelihood of clinical response to EGFR TKIs.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Gefitinib (Iressa) package insert[1]
- Gefitinib (Iressa) patient drug information (Chemocare)[4]
- Gefitinib (Iressa) patient drug information (UpToDate)[5]
History of changes in FDA indication
Non-small cell lung cancer - PARTIALLY WITHDRAWN
- 2003-05-05: Granted accelerated approval as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies. (Based on IDEAL2)
- 2005-06-17: Due to the negative confirmatory trial, access of this drug was restricted to patients currently receiving and benefiting from Iressa; patients who have previously received and benefited from Iressa; and previously enrolled patients or new patients in non-Investigational New Drug (IND) clinical trials approved by an IRB prior to June 17, 2005. (Based on ISEL)
- 2012-04-25: Accelerated approval withdrawn.
- 2015-07-13: FDA approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. (Based on IFUM and IPASS)
History of changes in EMA indication
- 2009-06-24: Initial marketing authorization as Iressa.
History of changes in Health Canada indication
- 2003-12-17: Initial notice of compliance with conditions
- 2009-12-18: Conditions were met
History of changes in PMDA indication
- 2011-11-25: Revised indication for the treatment of unresectable advanced or recurrent non-small cell lung cancer in patients with EGFR gene mutation.
Resistance and sensitivity mechanisms
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29. link to original article PubMed
- Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24;352(8):786-92. link to original article PubMed
Also known as
- Code name: ZD-1839
- Brand names: Cangib, Denrit, Geffy, Gefitec, Gefitero, Gefonib, Geftib, Geftican, Gefticip, Geftilon, Geftinat, Geftiwel, Iressa, KabiGef, Tykessa